Risankizumab more effective than ustekinumab for moderate-to-severe psoriasis

1. Risankizumab was associated with a significantly greater improvement in the primary endpoint of ≥90% reduction of the Psoriasis Area and Severity Index (PASI)...

Long term phototherapy can enhance treatment response in vitiligo

1. Examination of prospective studies found that a majority of patients with vitiligo had at least 25% re-pigmentation in response to phototherapy, with rates...

Effective subcutaneous C1-inhibitor for hereditary angioedema prophylaxis: The COMPACT trial

1. The self-administered, subcutaneous C1-inhibitor CSL830 demonstrated a dose-dependent high efficacy in the prophylactic treatment of hereditary angioedema (HAE) attacks compared to placebo. 2. CSL830...

Laser therapy may be effective in patients with infantile hemangiomas

1. In a retrospective review of over 140 infants with infantile hemangiomas (IH), combined neodymium-doped yttrium aluminum garnet laser and pulsed dye laser (Nd:YAG/PDL)...

Patients with psoriasis associated with increased systemic arterial and subcutaneous adipose inflammation

1. In a retrospective cohort study of 12 patients with psoriasis, 8F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) demonstrated significantly increased arterial inflammation...

Hidradenitis suppurativa associated with increased risk of subclinical atherosclerosis

1. In a prospective study of 62 patients with hidradenitis suppurativa (HS) and their matched controls, HS was associated with an increased risk of...

Autosomal dominant, maternal inheritance of infantile hemangioma

1. Pedigrees of families with infantile hemangioma (IH) were consistent with 2 distinct modes of transmission: autosomal dominant transmission and maternal inheritance, both with...

Anti-IL-17A therapy linked to sustained improvement in plaque psoriasis: The UNCOVER trials

1. Patients with moderate-to-severe plaque psoriasis treated with ixekizumab had significantly greater improvements in psoriasis compared to those treated with placebo at the end...

Pembrolizumab for the treatment of advanced melanoma

1. For patients with unresectable melanoma or metastatic melanoma that progressed despite treatment, pembrolizumab treatment resulted in objective response rate of 33%, 12-month progression-free...

Adjunctive TMP-SMX (Bactrim) associated with higher clinical cure rates for cutaneous abscesses

  1. Adjunctive TMP-SMX therapy in patients with cutaneous abscesses resulted in a significantly higher clinical cure rates compared to placebo. 2. Adjunctive TMP-SMX therapy...
licensing as small

Popular